Fritextsökning
Artiklar per år
Innehållstyper
-
Sprint Bioscience builds the molecules that will become new medicines
In Sprint Bioscience’s laboratory in Flemingsberg, Huddinge, molecules are being created that no one has ever built before. The company specializes in preclinical drug development and has, in several cases, succeeded in securing deals and partnerships with larger pharmaceutical companies.
-
“Ozempic babies” – myth or reality?
Have weight-loss drugs such as Ozempic led to a rise in unplanned pregnancies? Life Science Sweden takes a closer look.
-
Thermo Fisher Expands in Sweden – “We Are Sending a Clear Message”
The American life science giant Thermo Fisher Scientific has inaugurated a new distribution center in Uppsala. “By investing in increasing our capacity as well as our R&D here in Uppsala, we are building resilience for decades, not quarters,” says Santhosh Nair of Thermo Fisher.
-
More than 150 jobs cut as Merck scales back vaccin production
Merck & Co, known as MSD in Europe, is hitting the brakes following a sharp decline in demand for its HPV vaccine Gardasil. Production at its facility in Durham, North Carolina, is now being halted, with more than 150 employees facing redundancy.
-
Anna Törner: ”Drug prices – an important driver of innovation”
We live under the illusion that no price is too high when it comes to health, but that simply isn’t true, writes Anna Törner.
-
End of bone‑sawing? New laser cuts to record depths
Saw, drill and chisel are a bone surgeon’s best friends today – but soon the laser may also find its place in that toolbox. Researchers in Switzerland have discovered a method for cutting significantly deeper and faster with a surgical laser than has previously been possible.
-
Painkiller cuts recurrence risk by more than 50% – national guidelines updated
Sweden’s national guidelines for colon and rectal cancer have been updated — just nine months after the previous revision. The move follows new Swedish research showing that a daily dose of acetylsalicylic acid — the active ingredient in aspirin — can halve the risk of recurrence in a common subgroup of bowel cancer.
-
Novo Nordisk strengthens board after turbulent year
Changes to Novo Nordisk’s board continue. Following last year’s sweeping restructuring, the Danish obesity drugmaker is now nominating two new directors with extensive experience in the pharmaceutical industry.
-
A healthy society requires more than a new pill
Sarah Lidé on how medicines are essential – but a sustainable approach to healthy societies also depends on prevention and behavioural change
-
Asgard teaches tumours to self‑destruct – moving closer to clinical trials
Swedish biotech Asgard Therapeutics not only has an evocative name, but also a remarkably exciting approach to cancer treatment: getting tumour cells to reprogram themselves so that they become visible to the body’s immune system.
-
FDA leaders seek to scrap two-study requirement
A single pivotal study may be sufficient to secure approval for a new medicine in the United States. That is the message delivered by FDA Commissioner Marty Makary and the agency’s medical and scientific chief, Vinay Prasad, in an article in the New England Journal of Medicine.
-
Finland leads the way in the hunt for international top researchers
Several Nordic initiatives are currently under way to recruit international top researchers. Finland is making its largest national investment ever in attracting leading talent from abroad.
-
Dying man saved by artificial lung system
An external artificial lung system kept a critically ill man alive for two days until he could undergo a lung transplant. In the longer term, researchers hope the technology could transform the treatment of patients with life-threatening lung disease.
-
Swedish drug development projects in Phase III – studies to keep an eye on
Developing new medicines is, as we know, a lengthy and uncertain process, and only a fraction of all projects ever reach late clinical phase. But it does happen – and here we highlight a number of promising Swedish drug candidates currently in Phase III that are worth watching more closely.
-
“The US matters most – even in times of turbulence”
Tariffs, geopolitical uncertainty and rapidly changing trade conditions mean that Swedish life science companies need more routes into global markets – and faster support to understand what actually applies. That is the view of Johan Chun, newly appointed Head of Industry at Business Sweden.
-
Novo Nordisk Foundation commits billions to Danish life science incubator
The Novo Nordisk Foundation grants up to DKK 5.5 billion to life science and deep‑tech incubator Bioinnovation Institute (BII) in Copenhagen.
-
Investor Network Backs Early-Stage Nordic Innovation
Life Science Invest is expanding into the Nordic region and has secured SEK 31 million to invest in early-stage research companies. The capital will be invested in around ten life science companies over the coming year.
-
“There’s no magic wand” – The urgent need for new treatments
One in ten women with recurrent yeast infections develops a stubborn, hard-to-treat condition for which no effective therapies currently exist. At Danderyd Hospital, researcher Cathrin Alvendal at the Women’s Clinic research unit is working to change that. This is the second instalment in Life Science Sweden’s series on fungi.
-
Heart Monitoring in Breast Cancer – Essential or Excessive?
Trastuzumab and related drugs have transformed breast cancer treatment and dramatically improved survival rates. But the close cardiac monitoring required during treatment can be a heavy burden for both patients and healthcare systems. Dr. Andri Papakonstantinou is working to refine how doctors identify which patients truly need intensive follow-up.
-
Novo Nordisk tells staff to return to office
At the turn of the year, Novo Nordisk employees will no longer be able to work remotely. According to the company’s new CEO, the move is intended to accelerate decision-making and improve commercial execution as competition in the obesity drug market intensifies.
-
Novo Nordisk appoints Mike Doustdar as new CEO
The Danish pharmaceutical giant Novo Nordisk has appointed Mike Doustdar as its new CEO. At the same time, the company announced it was lowering its forecasts – which caused the stock to drop sharply on Wednesday.
-
Venomaid's rapid test aims to find the right snake bite treatment
Every six seconds, someone on our planet suffers a snake bite, and each time, a race against the clock begins. What kind of snake was it, and which antivenom can help? Danish company Venomaid Diagnostics is working hard to develop solutions to a problem that claims countless lives, especially in tropical countries.
-
Virology professor on the threat from X: ”The next pandemic could be worse“
The question is not if, but when we will be affected by a new unknown virus that causes yet another pandemic. Are we sufficiently prepared? "Absolutely not!", responds virologist Niklas Arnberg.
-
Höjdpunkter från Bioscience Göteborg 2025
En blandning mellan teknik, medicin, terapi och diagnostik. Så beskriver moderator Johan Rockberg vetenskapskonferensen, och sammanfattar några av de viktigaste insikterna från dagen.
BREAKING